Because, double homozygosity for the CFH and ARMS2 risk alleles account for more than 50% in the pathology of AMD [50], [51], we hypothesized that candidate gene screening in a subgroup of AMD patients and controls homozygous for CFH and ARMS2 wild-type alleles may help in identifying novel and independent genetic risk factors. The gene discussed is ARMS2; the disease is age-related macular degeneration.